Video Experimental Relacionado

Updated: Feb 7, 2026

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

Péptido Mimético de VEGF-Modificado Sistema Bifuncional de Nanopartículas para la Administración Dirigida de Fármacos

Maisituremu Tuerhan¹, Hailan Tian¹, Qinyi Lu¹

¹Department of Pharmacology, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.

ACS applied bio materials

|February 5, 2026

Abstract:

Aim: To develop a bioengineered nanomedicine integrating vascular regeneration and nitric oxide modulation for precision therapy of myocardial ischemia/reperfusion (I/R) injury. Materials and Methods: The nanomedicine (A-M@P-Q) was synthesized through mesoporous polydopamine/polydopamine (mPDA/PDA) coordination, functionalized with VEGF receptor (VEGFR)-targeting peptide (QK), and loaded with l-arginine. Therapeutic validation incorporated cellular hypoxia/reoxygenation (H/R) models and murine myocardial ischemia/reperfusion (I/R) studies, supported by in vivo biodistribution tracking and biosafety evaluation. Results: The A-M@P-Q nanomedicine demonstrated dual therapeutic efficacy: QK peptide promoted angiogenesis via VEGFR2 (Kdr) activation, while l-arginine restored NO homeostasis. In vitro studies revealed that both M@P-Q and A-M@P-Q enhanced NO production, downregulated cellular and mitochondrial ROS level, improved mitochondrial function, inhibited cell apoptosis, and promoted angiogenesis in H/R-triggered endothelial cells; however, A-M@P-Q exerted a stronger effect. Short-term in vivo studies found that A-M@P-Q enhanced phosphor-Kdr and NO level, inhibited cell apoptosis, and promoted early angiogenesis in myocardial I/R mice. Biodistribution study confirmed Kdr-targeted accumulation of M@P-Q nanoparticles in the infarcted myocardium. Systemic biocompatibility study showed negligible toxicity of the nanomedicine. Conclusion: This bifunctional nanosystem A-M@P-Q pioneers a coordinated therapeutic paradigm synchronizing neovascularization with NO promotion, establishing a clinically translatable strategy for I/R injury management through targeted myocardial repair.

Palabras clave:

VEGF l-arginina polidopamina mesoporosa infarto de miocardio administración dirigida de fármacos

Más Videos Relacionados

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

Published on: February 10, 2023

A Modified Simple Method for Induction of Myocardial Infarction in Mice

A Modified Simple Method for Induction of Myocardial Infarction in Mice

Published on: December 3, 2021

Videos de Conceptos Relacionados

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Drug Delivery: Overview

Drug Delivery: Overview

The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...

Drug Delivery: Enteral Route

Drug Delivery: Enteral Route

The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.

Drug Delivery: Parenteral Route

Drug Delivery: Parenteral Route

The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

Peptide Bonds

Peptide Bonds

A peptide bond covalently attaches amino acids through a dehydration reaction. One amino acid's carboxyl group and another amino acid's amino group combine, releasing a water molecule. The resulting bond is the peptide bond. The products that such linkages form are peptides. As more amino acids join this growing chain, the resulting chain is a polypeptide. Each polypeptide has a free amino group at one end. This end has the N-terminal, or the amino-terminal, and the other end has a free...